PARSIPPANY, NJ, Apr 29, 2010 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) announced today that in
accordance with NASDAQ Marketplace Rule 5635, the Company issued new
inducement stock options to one new hire.
The inducement stock options cover 5,000 shares of common stock and
are classified as non-qualified stock options with an exercise price
equal to the fair market value on the grant date. The options have a
10-year term and vest over four years as follows: 25 percent of these
options will vest on the date one year from the optionee's hire date,
the remainder will vest in monthly increments during the following 36
months (in all cases subject to the terms and conditions of the
Company's 2009 Equity Inducement Plan).
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the
treatment of critical care patients through the delivery of
innovative, cost-effective medicines to the worldwide hospital
marketplace. The Company markets Angiomax(R) (bivalirudin) in the
United States and other countries for use in patients undergoing
coronary angioplasty, and Cleviprex(R) (clevidipine butyrate)
injectable emulsion in the United States for the reduction of blood
pressure when oral therapy is not feasible or not desirable. The
Medicines Company's website is www.themedicinescompany.com.
Statements contained in this press release about The Medicines
Company that are not purely historical, and all other statements that
are not purely historical, may be deemed to be forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Without limiting
the foregoing, the words "believes," "anticipates" and "expects" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the Company's actual
results, levels of activity, performance or achievements to be
materially different from those expressed or implied by these
forward-looking statements. Important factors that may cause or
contribute to such differences include whether physicians, patients
and other key decision-makers will accept clinical trial results,
whether the Company is able to develop our global operations and
penetrate foreign markets whether Angiomax can successfully compete
with all categories of anticoagulant drugs and such other factors as
are set forth in the risk factors detailed from time to time in the
Company's periodic reports and registration statements filed with the
Securities and Exchange Commission including, without limitation, the
risk factors detailed in the Company's Annual Report on Form 10-K
filed on March 16, 2010, which are incorporated herein by reference.
The Company specifically disclaims any obligation to update these
forward-looking statements.
Contact:
Michael Mitchell
The Medicines Company
Phone: 973-290-6000
investor.relations@themedco.com
SOURCE: The Medicines Company
mailto:investor.relations@themedco.com
